Achilles Therapeutics 株価情報 (NASDAQ: ACHL)

最新ニュース Achilles Therapeutics (NASDAQ:ACHL) 株価情報

Achilles Therapeutics

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics PLC

News

Outset Medical Notified By FDA That All Issues Cited In Jul. 2023 Warning Letter Have Been Addressed

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.15) per share. This is a 15.38 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $4.53 million in sales this quarter. This is a 6.16 percent decrease over sales of $4.82 million the same period last year.

Earnings

POCI

Precision Optics Corp Q2 EPS $(0.15) Down From $(0.13) YoY, Sales $4.53M Down From $4.82M YoY

Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) announced today that it has received notice of an unsolicited "mini-tender" offer by TRC Capital Investment Corporation (TRC) dated February 11, 2025, to purchase up to 2,000,000 shares of Lamb Weston's common stock at a price of $55.95 per share in cash. TRC's offer price of $55.95 per share is approximately 4.34% lower than the $58.49 closing share price of Lamb Weston's common stock on February 10, 2025, the business day prior to the date of the offer. The offer represents approximately 1.4% of Lamb Weston's outstanding common stock as of that date.
Lamb Weston does not endorse TRC's unsolicited offer or the offer documentation. Lamb Weston is not affiliated with or associated in any way with TRC, its mini-tender offer or its offer documentation.

Management

Lamb Weston Responds To TRC Capital's "Mini-Tender" Offer To Purchase Up To 2M Shares Of Common Stock For A Price Of $55.95/Share; Says Lamb Weston Does Not Endorse TRC's Unsolicited Offer Or The Offer Documentation

WIIM

FROG

JFrog shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 adjusted EPS guidance above its estimate.

GameStop shares are trading higher following a CNBC report suggesting that the company is considering investing in Bitcoin and other cryptocurrencies.

Offerings

NPCE

Neuropace Announces That It Intends To Offer And Sell, In An Underwritten Public Offering, $65M Of Shares Of Its Common Stock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

CNBC: 'GameStop is considering investing in bitcoin and other cryptocurrencies, sources say'

Buybacks

Tennant Authorizes A New Share Repurchase Program Of Up To 2M Shares Of The Company's Common Stock, Effective February 11, 2025

LGCY

Legacy Education shares are trading lower. The company reported Q2 financial results.

Guidance

ICooper-Standard  Says 'Industry projections anticipate global light vehicle production will be lower in 2025 compared to 2024. Inflationary headwinds are expected to continue.'

Bowman Consulting Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWMN#NASDAQ">BWMN</a>), a national engineering services firm offering infrastructure, technology and program management solutions, has been awarded a four-year contract to provide on-call engineering design services for the University of New Mexico (UNM) with a total aggregate cap of $7.5 million.
Under the multi-year agreement, Bowman may provide surveying, civil engineering and subsurface utility engineering (SUE) services across UNM's extensive network of campuses, medical facilities, research hubs and academic institutions. These include UNM's Central and Branch campuses, UNM Hospital, the UNM Science &amp; Technology Park, South Campus, the UNM Comprehensive Cancer Center and the UNM Health Sciences Center. Bowman's expertise in these disciplines will support campus expansion, facility upgrades and long-term infrastructure planning.

Contracts

BWMN

Bowman Secures 4-Year ~$7.5M Contract To Provide Engineering Design Services For The University Of New Mexico

Cooper-Standard Sees FY25 Revenue $2.7B-$2.8B vs. $3.00B Est.

Piedmont Office Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDM#NYSE">PDM</a>) is looking for FY2025 FFO of $1.38-$1.44 vs $1.46 analyst estimate..

Piedmont Office Realty Sees FY2025 FFO $1.38-$1.44 vs $1.46 Est

ORRF

Orrstown Financial Services Announces That Adam L. Metz Has Been Promoted To Senior Executive Vice President And Chief Operating Officer Of The Company And Its Subsidiary Bank, Orrstown Bank. Will Succeed Thomas R. Quinn, Jr. As President And Chief Executive Officer Of The Company And The Bank Upon Mr. Quinn's Retirement On May 25, 2026.

IFRX

InflaRx shares are trading lower after the company announced a public offering, the size or amount not disclosed.

Piedmont Office Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDM#NYSE">PDM</a>) reported quarterly earnings of $0.37 per share which met the analyst consensus estimate. This is a 9.76 percent decrease over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $143.23 million which beat the analyst consensus estimate of $141.96 million by 0.90 percent. This is a 1.44 percent decrease over sales of $145.33 million the same period last year.

Earnings Beats

Piedmont Office Realty Q4 FFO $0.37, Inline, Sales $143.23M Beat $141.96M Estimate

Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) reported fourth-quarter financial results <a href="https://www.benzinga.com/earnings">after the market close Thursday.</a>
Here are the key highlights.
What Happened: Coinbase reported fourth-quarter revenue of $2.3 billion, up 88% quarter-over-quarter. The revenue figure beat a Street consensus estimate of $1.83 billion, according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021325&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company saw transaction revenue of $1.6 billion, up 172% quarter-over-quarter in the fourth quarter. Subscription and services revenue was $641 million, up 15% quarter-over-quarter and beating the company's guidance of a range of $505 million to $580 million.
Consumer trading volume was $94 billion in the fourth quarter, up 176% quarter-over-quarter. The company said this growth outpaced the U.S. spot market, which was up 126% quarter-over-quarter.
The company&#8217;s fourth-quarter GAAP earnings per share were $4.68 versus a Street consensus estimate of $1.81. 
Coinbase added several new cryptocurrencies to trade in the fourth quarter, with Pepe Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) and dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) highlighted in the report.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) made up the largest share of trading volume and transaction revenue at 27% and 27%, respectively. These figures were down from 37% and 35%, respectively, in the third quarter.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) made up 10% of trading volume in the quarter for Coinbase and 10% of transaction revenue, down from 15% and 13%, respectively, in the third quarter.
XRP Token (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) made up 14% of transaction revenue in the fourth quarter.
Coinbase had revenue of $6.6 billion for the full fiscal year, which was up 111% year-over-year. Full-year transaction revenue was $4 billion, up 162% year-over-year.
Read Also: <a href="https://www.benzinga.com/25/02/43670966/coinbase-q4-earnings-preview-trump-winning-2024-election-a-shot-in-the-arm-for-the-crypto-industry">Coinbase Q4 Earnings Preview: Trump Winning 2024 Election &#8216;A Shot In The Arm For The Crypto Industry&#8217;</a>
What's Next: Coinbase said it is seeing strong momentum thanks to regulatory clarity and a new White House administration, along with record high prices for several cryptocurrencies.
"It's the dawn of a new era for crypto. Crypto's voice was heard loud and clear in the U.S. elections," the company said.
The company said Donald Trump&#8216;s administration is moving fast to "fulfill its promise of making the U.S. the crypto capital of the planet."
Coinbase said it will double down on building, something it said it does best.
"Our goals in 2025 are to drive revenue, drive utility, and scale our foundations."
The company is guiding for first-quarter subscription and services revenue in a range of $685 million to $765 million.
Through Feb. 11, the company said it had transaction revenue of $750 million.
COIN Price Action: Coinbase stock is up 3.5% to $308.53 in after-hours trading Thursday versus a 52-week trading range of $146.14 to $349.75. Coinbase shares were up 8.4% to $298.11 during Thursday's trading session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43591727/coinbase-ceo-brian-armstrong-says-bitcoin-adoption-to-reach-billions-by-2030" target="_blank" rel="noreferrer noopener">Coinbase CEO Brian Armstrong Says Bitcoin Adoption To Reach ‘Billions' By 2030</a></li>
</ul>
Photo courtesy of Coinbase.

Movers

Trading Ideas

$BTC

$ETH

$PEPE

$WIF

$XRP

COIN

Coinbase Q4 Earnings Highlights: Trading Platform Welcomes 'Dawn Of A New Era For Crypto'

CNTM

ConnectM Technology shares are trading higher after the company announced it regained complained status with Nasdaq regarding its listing rule.

Ingersoll Rand Expects Full-Year 2025 Revenue Growth Of 3% - 5%, Adj EPS Of $3.38 - $3.50 (Est $3.48)

Earnings Misses

Cooper-Standard Holdings Q4 2024 Adj. EPS $(0.16), Sales $660.800M Miss $679.900M Estimate

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has halted its TIL-based cNeT therapy development and is closing its CHI...

Achilles Therapeutics Shifts Strategy, Seeks Alternatives

Achilles climbs after decision to find strategic alternatives

Achilles Therapeutics GAAP EPS of -$0.48

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has reported a cash position of $86.1 million as of September 30, 2024, ...

Achilles Therapeutics Explores Strategic Options Amid Financial Update

Achilles Therapeutics Plc ( ($ACHL) ) has released its Q3 earnings. Here is a breakdown of the information Achilles Therapeutics Plc presented to i...

Achilles Therapeutics Reports Q3 2024 Financial Results

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has successfully regained compliance with Nasdaq's minimum bid price req...

Achilles Therapeutics Regains Nasdaq Compliance, Boosting Investor Confidence

Achilles Therapeutics (ACHL) announced that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Canc...

Achilles Therapeutics sells technology assets to AstraZeneca for $12M

Achilles Therapeutics sells technology assets to AstraZeneca

Achilles Therapeutics ( ($ACHL) ) just unveiled an update. Achilles Therapeutics has sold its technology assets, including data and samples from th...

Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million

The latest announcement is out from Achilles Therapeutics ( ($ACHL) ). Achilles Therapeutics announced the resignation of three members from its Bo...

Achilles Therapeutics Announces Board Resignations Amid Strategic Realignment

ACHL

AZNCF

Health Care

Press Releases

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

Comments

Achilles Therapeutics

ニュース

最新ニュース Achilles Therapeutics (NASDAQ:ACHL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル